Skip to main content
Premium Trial:

Request an Annual Quote

Bionas, Primacyt, Institut Pasteur-Korea, Cellectricon, Beckman Coulter, Aurora Biotechnologies

Bionas and Primacyt to Develop Cell-Based Assay to Study Hepatotoxicity
Bionas and Primacyt said this week that they will jointly develop a cell-based assay using human liver cells to predict hepatotoxic effects of drugs and chemicals.
Primacyt, based in Schwerin, Germany, will supply the hepatocytes. The hepatocytes will be cultivated on Bionas metabolic chips with chemically defined media from Primacyt.
The chips will be evaluated in the Bionas 2500 analyzing system. The hepatocytes can be reused for other experiments in the system, the companies said.
Financial details were not disclosed.

Institut Pasteur-Korea to Use IDBS Data Management Software
IDBS said this week that Institut Pasteur-Korea has purchased the company’s ActivityBase data-management software for use in its high-content and high-throughput screening operations.
IP-K will use ActivityBase to consolidate chemistry information and screening results, including those from microscopy-based screens, in a single Oracle database, IDBS said.
Terms of the deal were not disclosed.

Cellectricon Wins $316K Swedish Grant to Develop Microfluidic GPCR Screening Platform
The Swedish government awarded Cellectricon a SEK 2.3 million ($316,218) research grant to develop its microfluidics platform for high-resolution GPCR screening, the company said this week.
The VINNOVA grant was made by the Swedish Governmental Agency for Innovation Systems.
Cellectricon is based in Gothenburg, Sweden.

Beckman Coulter to Distribute Aurora Biotechnologies' ChemLib Microplates
Aurora Biotechnologies this week said that Beckman Coulter has become a global distributor of Aurora’s ChemLib line of microplates.
In a statement, Beckman said that Aurora’s ChemLib microplates, when packaged with Beckman’s liquid-handling and detection instrumentation technologies, “allow us to offer our customers a total miniaturization solution."
Financial or geographical terms of the agreement were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.